Arcapita

Carta exists to solve one of the biggest inefficiencies in finance: the fragmentation of private capital markets. While public markets enjoy real-time connectivity, transparency, and speed, private markets still rely on spreadsheets, manual processes, and disconnected systems. This fragmentation creates inefficiencies that cost founders, investors, and employees billions annually. Carta's ERP for private capital changes this by connecting data, workflows, and people across the entire ecosystem - from GPs and LPs to CEOs, CFOs, employees, and advisors - on one unified platform that brings the sophistication of public markets to private capital. Trusted by over 50,000 companies in more than 160 countries, Carta manages $4.2 trillion+ in total equity value and serves 85% of US unicorns. The platform addresses the complete lifecycle of private capital, from cap table management and equity compensation for startups, to fund administration, portfolio valuations, and investor reporting for venture capital and private equity firms. By digitizing paper-based processes and creating an interconnected ownership graph, Carta is making private markets more transparent, accessible, and efficient - ultimately creating more owners and unlocking liquidity for the modern economy.

ARCHIMED is a global private equity firm dedicated exclusively to healthcare industries, founded in 2014 with a singular mission: to accelerate the development of healthcare solutions that benefit patients worldwide. The firm focuses on small-cap and mid-cap growth buyout transactions across eight targeted healthcare sectors - Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, MedTech, Pharma Services, and Animal & Environmental Health. What sets ARCHIMED apart is its integrated approach combining operational, medical, scientific, and financial expertise, allowing the firm to serve as both a strategic and financial partner to healthcare businesses across Europe, North America, and Asia. With over 200 team members representing 35+ nationalities, ARCHIMED manages €8 billion across its funds and has invested in more than 80 companies representing over €50 billion in combined value. The firm's strategy is built on a proprietary market segmentation called MedSeg, which splits healthcare industries into 400+ sub-sectors that are individually assessed and prioritized. ARCHIMED's transatlantic platform supports portfolio companies through internationalization, innovation, M&A, and operational excellence. The firm delivers superior returns to investors - all ARCHIMED funds rank as top-decile performers - while maintaining a strong commitment to impact investing through its EURÊKA Foundation, which returns 5% of carried interest profits to the community.